Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. Common Stock（ACRV）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ACRV · 截至 2026年6月9日
活动摘要
买入笔数
3
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Acrivon Therapeutics, Inc. Common Stock内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ACRV 季度内部人买卖趋势
ACRV 内幕交易卖出 · ACRV 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ACRV CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ACRV 高管卖出股份 · ACRV 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 21, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 13,729 | $25K | Form 4 |
| May 18, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | TOMSICEK MICHAEL JOHN Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Shacham Sharon Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Palani Santhosh Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Magovcevic-Liebisch Ivana Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | DiRocco Derek Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | BAUM CHARLES M Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Peterson Katharine CAO | Award | 14,227 | — | Form 4 |
| May 18, 2026 | Mirza Mansoor Raza Chief Medical Officer | Award | 38,817 | — | Form 4 |
| May 18, 2026 | Miller Mary Chief Legal Officer | Award | 49,830 | — | Form 4 |
| May 18, 2026 | Levy Adam D. CFO | Award | 46,167 | — | Form 4 |
| May 18, 2026 | Gamelin Erick Chief Development Officer | Award | 38,584 | — | Form 4 |
| May 18, 2026 | Devroe Eric COO | Award | 72,981 | — | Form 4 |
| May 18, 2026 | Blume-Jensen Peter President and CEO · Director | Award | 180,095 | — | Form 4 |
| May 18, 2026 | Blume-Jensen Peter President and CEO · Director | Award | 72,706 | — | Form 4 |
| May 14, 2026 | Peterson Katharine CAO | Other | 99 | $190 | Form 4 |
| May 14, 2026 | Miller Mary Chief Legal Officer | Other | 184 | $353 | Form 4 |
| May 14, 2026 | Gamelin Erick Chief Development Officer | Other | 404 | $776 | Form 4 |
| May 14, 2026 | Devroe Eric COO | Other | 613 | $1K | Form 4 |
| May 14, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 1,253 | $2K | Form 4 |
| May 14, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 490 | $941 | Form 4 |
| Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Award | 3,888,888 | $7.00M⚡ | Form 4 |
| Apr 17, 2026 | Miller Mary Chief Legal Officer | Other | 558 | $993 | Form 4 |
| Feb 21, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 14,265 | $22K | Form 4 |
Blume-Jensen Peter
President and CEO · Director
日期
May 21
股数
13,729
均价
$1.79
总金额
$25K
Blume-Jensen Peter
President and CEO · Director
日期
May 14
股数
1,253
均价
$1.92
总金额
$2K
Blume-Jensen Peter
President and CEO · Director
日期
May 14
股数
490
均价
$1.92
总金额
$941
Blume-Jensen Peter
President and CEO · Director
日期
Feb 21
股数
14,265
均价
$1.53
总金额
$22K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ACRV 内幕交易
ACRV 内幕交易
Acrivon Therapeutics, Inc. Common Stock（ACRV）内幕交易数据来源于公司内部人（包括Blume-Jensen Peter (President and CEO · Director), Miller Mary (Chief Legal Officer), Devroe Eric (COO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ACRV内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Acrivon Therapeutics, Inc. Common Stock机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ACRV 内幕交易 · 5个问题Acrivon Therapeutics, Inc. Common Stock（ACRV）的内部人包括高管和董事，如Blume-Jensen Peter (President and CEO · Director), Miller Mary (Chief Legal Officer), Devroe Eric (COO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026